Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor

PURPOSE: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab). METHODS: This is a retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Da Ru Chi, Lee, Dong Kyu, Kim, Soon Hyun, You, Yong Sung, Kwon, Oh Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Ophthalmological Society 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520865/
https://www.ncbi.nlm.nih.gov/pubmed/26240506
http://dx.doi.org/10.3341/kjo.2015.29.4.226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520865/
https://www.ncbi.nlm.nih.gov/pubmed/26240506
http://dx.doi.org/10.3341/kjo.2015.29.4.226

Ejemplares similares